



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : Lalruatdika Varte, Drugs Inspector
Drugs Inspector
Office of the Chief Medical Officer, Kolasib, Mizoram -
796 082
- Serial No. and date of Inspector's memorandum : KLB/22/2025/IPA/DRUGS , 17-MAR-2025
- Number of Sample : NIL
- Date of receipt : 17-APR-2025
- Names of drugs purporting to be contained in the sample : Telmisartan and Hydrochlorothiazide Tablets IP

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-GUW/LS/2025-26/0530	26/543	TDH1494D	Nov-2024 Oct-2026	NA	Pulse Pharmaceuticals Pvt. Ltd., Khasra No. 400, 407, 409, Karondi, Roorkee, Uttarakhand-247 667

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 14-May-2025 To 11-Jul-2025

COMPOSITION : Each bilayered tablet contains:
Telmisartan IP 40 mg
Hydrochlorothiazide IP 12.5 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Off white and pink colored, bi-layered, bi-convex, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Telmisartan and Hydrochlorothiazide.	NA
3	Average weight	0.4469 g	NA
4	Uniformity of weight	Complies.	±5 % of Average weight
5	Dissolution (for Telmisartan)	Complies.	NLT 80 % of claim
6	Dissolution (For Hydrochlorothiazide)	Complies.	NLT 80 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Telmisartan	40.03 mg/Tablet	40 mg/Tablet	100.075	95 % to 105 %	I.P. 2022
2	Hydrochlorothiazide	13.33 mg/Tablet	12.5 mg/Tablet	106.64	90 % to 107.5 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 05-AUG-2025

Rinku Kalita
GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----

